Meg Jardine's Publications

• Estimating the population-level kidney benefits of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease in Australian primary care

  Preprints

  2023

• WCN23-1085 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATY- THE ALIGN STUDY

  Journal articles

  2023

  Kidney International Reports

• WCN23-0574 THE ELLEN MEDICAL DEVICES AFFORDABLE POINT-OF-CARE PERITONEAL DIALYSIS SYSTEM - A PILOT STUDY

  Journal articles

  2023

  Kidney International Reports

• TREATMENT EFFECT OF CANAGLIFLOZIN FOR PATIENTS ON THERAPY FOR HEART FAILURE: POOLED ANALYSIS OF THE CANVAS PROGRAM AND CREDENCE TRIAL

  Journal articles

  2023

  Journal of the American College of Cardiology

• Study protocol for Vascular Access outcome measure for function: a vaLidation study In hemoDialysis (VALID): A multi-center, multinational validation study to assess the accuracy and feasibility of measuring vascular access function in clinical practice

  Journal articles

  2022

  BMC Nephrology

• Digital health technologies to support medication adherence in chronic kidney disease

  Journal articles

  2022

  Nephrology

• Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program

  Journal articles

  2022

  Diabetes, Obesity and Metabolism

• Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial

  Journal articles

  2022

  Trials

• Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

  Journal articles

  2022

  The Lancet

• Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria

  Journal articles

  2022

  Journal of the American College of Cardiology

• CANAGLIFLOZIN AND DIURETIC USE IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL

  Conference Abstracts

  2022

  NEPHROLOGY

• Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

  Journal articles

  2022

  Journal of the American Heart Association

• SGLT2 inhibitors and finerenone: one or the other or both?

  Journal articles

  2022

  Nephrology Dialysis Transplantation

• The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial

  Journal articles

  2022

  Diabetes and Metabolism

• Sex differences in chronic kidney disease prevalence in Asia: A systematic review and meta-analysis

  Journal articles

  2022

  Clinical Kidney Journal

• Trimming the fat: Is there a health economic case for the use of new lipid-lowering drugs in chronic kidney disease? A scoping review

  Journal articles

  2022

  Clinical Kidney Journal

• Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial

  Journal articles

  2022

  JAMA - Journal of the American Medical Association

• Risk factors for incident kidney disease in older adults: an Australian prospective population-based study

  Journal articles

  2022

  Internal Medicine Journal

• A Novel Risk Prediction Model for Severe Acute Kidney Injury in Intensive Care Unit Patients Receiving Fluid Resuscitation

  Journal articles

  2022

  Frontiers in Cardiovascular Medicine

• Premature Death in Kidney Transplant Recipients: The Time for Trials is Now

  Journal articles

  2022

  Journal of the American Society of Nephrology

• Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice

  Journal articles

  2022

  International Journal of Cardiology

• SGLT2 inhibitors may prevent diabetes

  Journal articles

  2022

  Nature Reviews Nephrology

• Digital health and artificial intelligence in kidney research: A report from the 2020 Kidney Disease Clinical Trialists (KDCT) meeting

  Journal articles

  2022

  Nephrology Dialysis Transplantation

• Prior Cardiovascular TreatmentsA Key Characteristic in Determining Medication Adherence After an Acute Myocardial Infarction

  Journal articles

  2022

  Frontiers in Pharmacology

• Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial

  Journal articles

  2022

  Clinical Journal of the American Society of Nephrology

• Antiplatelet agents for chronic kidney disease

  Journal articles

  2022

  Cochrane Database of Systematic Reviews